Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Profiling PARP inhibitors

Nature Biotechnology volume 30, pages 249–250 (2012)Cite this article

Subjects

An Erratum to this article was published on 10 April 2012

This article has been updated

A comprehensive study of ligand binding to the human PARP family of proteins reveals the molecular basis of inhibitor selectivity and promiscuity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Understanding the molecular basis for specific and nonspecific PARP inhibition.

Change history

  • 07 March 2012

    In the print version of this article, MD Anderson is listed as Maryland Anderson. The error has been corrected in the HTML and PDF versions of the article before online publication.

References

  1. Jagtap, P. & Szabo, C. Nat. Rev. Drug Discov. 4, 421–440 (2005).

    Article  CAS  Google Scholar 

  2. Wahlberg, E. et al. Nat. Biotechnol. 30, 283–288 (2012).

    Article  CAS  Google Scholar 

  3. Chambon, P., Weill, J.D. & Mandel, P. Biochem. Biophys. Res. Commun. 11, 39–43 (1963).

    Article  CAS  Google Scholar 

  4. Hottiger, M.O., Hassa, P.O., Lüscher, B., Schüler, H. & Koch-Nolte, F. Trends Biochem. Sci. 35, 208–219 (2010).

    Article  CAS  Google Scholar 

  5. Kleine, H. et al. Mol. Cell 32, 57–69 (2008).

    Article  CAS  Google Scholar 

  6. Huang, S.M. et al. Nature 461, 614–620 (2009).

    Article  CAS  Google Scholar 

  7. Fong, P.C. et al. N. Engl. J. Med. 361, 123–134 (2009).

    Article  CAS  Google Scholar 

  8. Thomas, H.D. et al. Mol. Cancer Ther. 6, 945–956 (2007).

    Article  CAS  Google Scholar 

  9. Penning, T.D. et al. J. Med. Chem. 52, 514–523 (2009).

    Article  CAS  Google Scholar 

  10. Shultz, M.D. J. Med. Chem. 55, 1127–1136 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Philip Jones is at the Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, Texas, USA.,

    Philip Jones

Authors
  1. Philip Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip Jones.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jones, P. Profiling PARP inhibitors. Nat Biotechnol 30, 249–250 (2012). https://doi.org/10.1038/nbt.2138

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2138

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research